Journal Finder

For 30 years Drugs & Aging has been delivering essential information on the most important aspects of drug therapy to researchers and healthcare professionals involved in the care of older patients.

Through a program of reviews and original research articles, the journal addresses major issues relating to drug therapy in older adults, including the management of specific diseases or disorders, particularly those associated with aging, age-related physiological changes impacting drug therapy, and issues related to drug utilization and prescribing.

As a hybrid journal, Drugs & Aging does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).

Drugs & Aging offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).

Drugs & Therapy Perspectives provides concise, authoritative review articles to aid drug formulary and prescribing decisions. It is a digest of the latest drug knowledge covering the most important aspects of clinical therapeutics, including:Questions and answers on the clinical use of drugs.Comparisons of the features of various drugs, using differential feature tables.Current thinking on disease management.Step-by-step clinical decision-making, illustrated with patient care algorithms.First reports of serious adverse drug reactions.Clinically useful pharmacodynamics and pharmacokinetics.Developments in pharmacoeconomics and other research that have a bearing on clinical practice.All material is prepared by Adis editors and medical writers, unless otherwise noted. The preparation of material is not supported by any external funding. All review articles are subject to peer review by members of the journal's international editorial board and/or other experts.

Drugs - Real World Outcomes targets research involving the use of real-world data to evaluate health outcomes and inform healthcare decision-making, with a particular focus on healthcare-related 'big data'. Drugs - Real World Outcomes has a broad scope, encompassing studies investigating drug utilisation, patterns of prescribing, pharmacovigilance, treatment guideline adherence, benefit-risk assessments, comparative effectiveness and economic analyses.

The original papers published in the European Archives of Psychiatry and Clinical Neuroscience deal with all aspects of psychiatry and related clinical neuroscience.Clinical psychiatry, psychopathology, epidemiology as well as brain imaging, neuropathological, neurophysiological, neurochemical and moleculargenetic studies of psychiatric disorders are among the topics covered. Thus both the clinician and the neuroscientist are provided with a handy source of information on important scientific developments.Fields of interest: Psychiatry (psychopathology, clinical psychiatry, epidemiology, genetics), neurological sciences (neuropathology, neurophysiology, neurochemistry, neuropsychology, neurology, neurosurgery).

The European Journal of Clinical Pharmacology publishes original papers, short communications, and letters to the editors on all aspects of clinical pharmacology and drug therapy in humans. Coverage includes therapeutic trials; pharmacokinetics; drug metabolism; adverse drug reactions; drug interactions; all aspects of drug development; prescribing policies; pharmacoepidemiology; and matters relating to the safe use of drugs. Data from animal experiments are published only in the context of parallel experiments in man reported in the same paper. The journal also publishes review articles on special problems related to these areas, and encourages debate on controversial issues.

The Official Journal of the European Society of Contraception and Reproductive Health, The European Journal of Contraception and Reproductive Health Care publishes original peer-reviewed research papers as well as review papers and other appropriate educational material.The Editors welcome submissions from members of the European Society of Contraception and Reproductive Health and also from non-members anywhere in the world.Peer Review Policy:All published research articles in this journal have undergone rigorous peer review, based on initial editor screening and anonymous reviewing by independent reviewers.

The European Journal of Drug Metabolism and Pharmacokinetics addresses all aspects of pre-clinical and clinical pharmacokinetics, including drug disposition, drug metabolism, drug transport, drug interactions, bioavailability and biopharmacy. The journal welcomes publications in the field of pharmacokinetic modeling. Analytical methods validation and bioequivalence studies will not be considered for publication. The journal publishes original articles, short preliminary communications, review articles on special topics, and conference proceedings.The European Journal of Drug Metabolism and Pharmacokinetics publishes four issues a year.

European Neuropsychopharmacology provides a medium for the prompt publication of articles in the field of neuropsychopharmacology. Its scope encompasses clinical and basic research relevant to the effects of centrally acting agents in its broadest sense.European Neuropsychopharmacology is the official journal of the European College of NeuropsychopharmacologyElectronic usage:An increasing number of readers access the journal online via ScienceDirect, one of the world's most advanced web delivery systems for scientific, technical and medical information.Average monthly article downloads for this journal: 24,961** Figure is a monthly average of full-text articles downloaded from ScienceDirect between July 2012 and July 2013

Experimental and Clinical Psychopharmacology publishes advances in translational and interdisciplinary research on psychopharmacology and drug abuse. The scope of research in these areas continues to expand and to benefit from collaborations across a broad range of disciplines, including behavioral science, brain imaging, genetics, neuroendocrinology, neuroscience, and pharmacology.One goal of the journal is to encourage increased attention to biologic factors that may influence both the pharmacodynamic and the pharmacokinetic effects of drugs. Recent research has shown the importance of examining the effects of sex and menstrual/estrous cycle phase on the effects of abused drugs, as well as responses to medications for the treatment of drug abuse and the alleviation of pain.The journal publishes original reports on the development and evaluation of new pharmacotherapies, the influence of genetics and hormones on responses to abused drugs and treatment medications, the pharmacological management of pain, and brain imaging studies of the neural correlates of drug effects.The journal will focus on clinical laboratory studies and controlled clinical medication trials as well as basic preclinical experiments on psychopharmacology and drug abuse.The journal also will include comprehensive and integrative reviews of advances in research on psychopharmacology. These reviews should provide a broad perspective on a particular area of research or trace the development of critical concepts and experimental approaches.Each year, the journal will recognize young investigators who are recipients of the Young Psychopharmacologist Award or the Best Dissertation Award, as well as midcareer and senior scientists who receive the Brady–Schuster Award from APA Division 28, Psychopharmacology and Substance Abuse. Awardees will be invited to submit a review paper based on their award-winning research.The journal may occasionally publish innovations in psychopharmacology that report a novel method, measure, or result. Commentary on the nature and implications of the innovation may be invited.The overall goal is to provide a forum for innovative clinical and preclinical research that advances our understanding of the behavioral and biological determinants of the effects of drugs.

Expert Opinion on Drug Safety ranks #100 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development. * Reviews covering occurrence, management and prevention of drug-associated adverse events; risk-benefit analyses of individual drugs and drug classes; safety in 'at-risk' patient populations; comparative tolerability studies; pharmacovigilance and pharmacoepidemiological studies * Drug Safety Evaluations reviewing the safety data on a particular drug * Original Research papers reporting the results of post-marketing surveillance and other safety studies looking at specific drugs, populations and outcomes; methods for the detection and evaluation of drug-associated adverse eventsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in monitoring drug safety.Read More: http://informahealthcare.com/page/Description?journalCode=eds.

Expert Opinion on Emerging Drugs ranks #69 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.Each review article is structured to include: * Concise background to the subject matter * Assessment of medical need for alternative or novel therapies * Assessment of the market and anticipated changes over time * Summary of current research goals * Outline of the scientific rationale for the approach(es) considered< * Analysis of the competitive environment * Discussion of potential development issues * The author’s expert opinion on the potential impact emerging therapies will have on the current management of specific diseasesThe audience consists of pharmaceutical and academic scientists, research planners, pharmaceutical product mangers, clinical opinion leaders and healthcare planners.

Expert Opinion on Investigational Drugs ranks #35 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. * Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trialsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.

Expert Opinion on Orphan Drugs will be an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs.

Expert Opinion on Pharmacotherapy ranks #120 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Pharmacotherapy (ISSN 1465-6566 [print], 1744-7666 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.The Editors welcome: * Reviews covering new drugs/drug classes for specific diseases, from development Phase III to those that have been available to pharmacopoeia for up to 5 years, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase III and IV clinical trials and pharmacologically based studies with a strong link to clinical practiceThe audience consists of research and development, regulatory and marketing decision makers in the pharmaceutical industry and decision makers in healthcare provision.